Christopher R. Heery
- Oncology top 1%
- Immunology top 1%
- Molecular Biology top 10%
- Pulmonary and Respiratory Medicine top 2%
- Radiology, Nuclear Medicine and Imaging top 5%
- Co-authors
- James L. GulleyJeffrey SchlomRavi A. MadanRenee N. DonahueCaroline JochémsJennifer L. MartéKwong Y. TsangItalia Grenga
- Topics
- Cancer Immunotherapy and Biomarkers (52 papers)Immunotherapy and Immune Responses (49 papers)CAR-T cell therapy research (27 papers)
- Cited by
- OncologyImmunologyVirology
- Partner nations
- United StatesGermanySpain
In The Last Decade
Christopher R. Heery
110 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 96
- Oncology 2.5k
- Immunology 1.7k
- Molecular Biology 876
- Pulmonary and Respiratory Medicine 854
- Radiology, Nuclear Medicine and Imaging 292
Countries citing papers authored by Christopher R. Heery
This map shows the geographic impact of Christopher R. Heery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher R. Heery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher R. Heery more than expected).
Fields of papers citing papers by Christopher R. Heery
This network shows the impact of papers produced by Christopher R. Heery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher R. Heery. The network helps show where Christopher R. Heery may publish in the future.
Co-authorship network of co-authors of Christopher R. Heery
This figure shows the co-authorship network connecting the top 25 collaborators of Christopher R. Heery. A scholar is included among the top collaborators of Christopher R. Heery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher R. Heery. Christopher R. Heery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 2 | |
| 4 | 14 | |
| 5 | 183 | |
| 6 | 45 | |
| 7 | 116 | |
| 8 | Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumorsbreakdown → | 327 |
| 9 | 51 | |
| 10 | 12 | |
| 11 | 3 | |
| 12 | 26 | |
| 13 | 360 | |
| 14 | 104 | |
| 15 | 1 | |
| 16 | 68 | |
| 17 | 101 | |
| 18 | 64 | |
| 19 | 101 | |
| 20 | 17 |
About Christopher R. Heery
Christopher R. Heery is a scholar working on Immunology, Oncology and Pulmonary and Respiratory Medicine, having authored 112 papers that have together received 3.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (52 papers), Immunotherapy and Immune Responses (49 papers) and CAR-T cell therapy research (27 papers). The work is most often cited by research in Oncology (2.5k citations), Immunology (1.7k citations) and Virology (138 citations). Christopher R. Heery has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include James L. Gulley, Jeffrey Schlom, Ravi A. Madan, Renee N. Donahue, Caroline Jochéms, Jennifer L. Marté, Kwong Y. Tsang, Italia Grenga, Massimo Fantini and Marijo Bilušić. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.